December 17, 2023 — cybernewschronicle.com — For patients living with sickle cell disease and beta thalassemia, the calendar flipped to a new page on December 15, 2023. That was the day the U.S. Food and Drug Administration granted regulatory approval to exagamglogene autotemcel, or exa-cel — a treatment built on CRISPR gene editing technology. The decision by the FDA did not come out of nowhere.
It capped years of clinical work by CRISPR Therapeutics AG, the Swiss-American company that developed the therapy. But the approval itself now sets off a cascade of consequences that reach far beyond the company’s headquarters in Zug, Switzerland.
CRISPR Therapeutics was one of the first firms to take the CRISPR gene editing platform and try to turn it into real medicine. That bet paid off. The company now employs roughly 500 people across offices in Zug; Boston, Massachusetts; San Francisco, California; and London, United Kingdom.
Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award in 2022 — a sign that the production side of the operation had already been built to a high standard before the FDA gave the green light. That facility is now tasked with scaling up to meet demand from patients who have been waiting for a therapy that attacks the root cause of their disease rather than just managing symptoms.
The ripple effects hit several groups at once. For patients, the approval means a one-time treatment that uses CRISPR to edit a patient’s own blood stem cells. That is a different proposition from lifelong transfusions or daily pills.
For doctors, the approval creates a new treatment pathway that requires specialized infrastructure — the cells must be collected, genetically modified in a lab, and then infused back into the patient. Not every hospital has that capability. For insurers and health systems, the price tag of a gene therapy that could be curative will force hard decisions about coverage and access.
Regulators in other countries are now under pressure. The FDA’s decision sets a precedent.
The European Medicines Agency and other national health authorities will face questions from patient groups and investors about when they will follow suit. CRISPR Therapeutics has a global footprint, with offices in London and Zug, but regulatory approval in the United States is the most significant commercial prize. The company’s lead program, exa-cel, was formerly known as CTX001.
The name change reflects a shift from an experimental compound to a branded product with marketing approval. The biotechnology sector is watching closely.
CRISPR Therapeutics has established itself as a pioneer, but the real test begins now: manufacturing the therapy reliably, distributing it to treatment centers, and tracking long-term outcomes in patients. The Framingham facility that won the FOYA award in 2022 will be central to that effort. The company’s roughly 500 employees will need to execute on a scale that no CRISPR-based company has managed before.
Competitors are also taking note. Other gene-editing companies have programs in earlier stages of development. The FDA approval of exa-cel validates the entire platform — not just for blood disorders but potentially for other genetic diseases where CRISPR could be applied.
The consequences of December 15, 2023, will unfold over years, not weeks. Patients and doctors will learn what the therapy can and cannot do in the real world.
Payers will decide who gets it. And regulators in other countries will move at their own pace. The approval opened a door.
Now people have to walk through it.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “FDA Approves CRISPR-Based Gene Therapy for Sickle Cell and Beta Thalassemia”, “description”: “For patients living with sickle cell disease and beta thalassemia, the calendar flipped to a new page on December 15, 2023. That was the day the U.S. Food and D”, “datePublished”: “2023-12-17T15:00:00+00:00”, “author”: {“@type”: “Person”, “name”: “InfoPulse Today”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”}}
